Inventor · Hillsborough, NC, US

Jay Copeland Strum

51Patents
12h-index
21Co-inventors
80Inventor score

Filing activity: Nov 17, 2011 → Apr 20, 2023

Most-cited inventions

PatentTitleAreaCited byStatus
US8598186B2 CDK inhibitors Chemistry; Metallurgy 46 Active
US8598197B2 CDK inhibitors Chemistry; Metallurgy 44 Active
US8691830B2 CDK inhibitors Chemistry; Metallurgy 42 Active
US8822683B2 CDK inhibitors Chemistry; Metallurgy 40 Active
US8829012B2 CDK inhibitors Chemistry; Metallurgy 40 Active
US9102682B2 CDK inhibitors Chemistry; Metallurgy 28 Active
US9487530B2 Transient protection of normal cells during chemotherapy Human Necessities 23 Active
US9499564B2 CDK inhibitors Chemistry; Metallurgy 20 Active
US9464092B2 Transient protection of normal cells during chemotherapy Human Necessities 20 Active
US9481691B2 CDK inhibitors Chemistry; Metallurgy 20 Active
US9527857B2 HSPC-sparing treatments for RB-positive abnormal cellular proliferation Human Necessities 18 Active
US9717735B2 Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation Chemistry; Metallurgy 12 Active
US10085992B2 Transient protection of normal cells during chemotherapy Human Necessities 10 Active
US9931345B2 Transient protection of normal cells during chemotherapy Human Necessities 10 Active
US10076523B2 HSPC-sparing treatments for RB-positive abnormal cellular proliferation Human Necessities 9 Active
US10189849B2 CDK inhibitors Chemistry; Metallurgy 9 Active
US10189850B2 CDK inhibitors Chemistry; Metallurgy 8 Active
US10189851B2 CDK inhibitors Chemistry; Metallurgy 8 Active
US9957276B2 CDK inhibitors Chemistry; Metallurgy 7 Active
US10231969B2 Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors Human Necessities 7 Active
US10413547B2 Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors Human Necessities 6 Active
US10618905B2 Pyrimidine-based compounds for the treatment of cancer Chemistry; Metallurgy 4 Active
US11090306B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors Human Necessities 3 Active
US10988479B1 Morphic forms of trilaciclib and methods of manufacture thereof Chemistry; Metallurgy 3 Active
US10829490B2 Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents Emerging Cross-Sectional Technologies 2 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.